<DOC>
	<DOCNO>NCT00626639</DOCNO>
	<brief_summary>Oral Mucositis associate adjuvant radiation concurrent chemotherapy postoperative Head Neck set</brief_summary>
	<brief_title>A Study Palifermin Reduction Oral Mucositis Patients With Locally Advanced Head Neck Cancer Receiving Postoperative Radiotherapy Concurrent Chemotherapy</brief_title>
	<detailed_description>This study consist 2 phase . The acute oral mucositis ( OM ) evaluation phase include time randomization time severe OM ( WHO Grade 3 4 ) resolution ( Week 12 Week 15 participant whose severe OM resolve Week 12 ) . In acute OM evaluation phase , participant randomize receive either single IV bolus dose palifermin placebo 120 Î¼g/kg , 3 day start radiotherapy , plus 7 once-weekly palifermin placebo dose dose level 7-week radio/chemotherapy course . In long-term follow phase , participant follow death , withdrawal consent , loss follow-up . The long-term follow phase still ongoing .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>History newly diagnose histologically confirm squamous cell carcinoma ( American Joint Committee Cancer [ AJCC ] Stage II , III , IVA , IVB ) involve either oral cavity , oropharynx , nasopharynx , hypopharynx , larynx , post surgical resection ( R0 , R1 ) Scheduled receive adjuvant concurrent chemoradiation treatment within 12 week surgery Highrisk subject define presence least one following : R1 resection margin ; T3 T4 tumor stage ; 3 positive lymph node metastasis ; &lt; 3 lymph node metastases extracapsular extension disease Radiation treatment field receive plan dose least 50Gy area oral cavity/oropharynx mucosa visualize Tumors lip , paranasal sinus , salivary gland , unknown primary tumor Metastatic disease ( M1 ) / Stage IV C Presence history primary malignancy History pancreatitis Prior radiotherapy site disease Prior chemotherapy Other investigational procedure Thirty day less since receive investigational product device another clinical trial . Current enrollment another clinical trial permit unless sole purpose trial longterm followup/survival data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>palifermin</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Oncology</keyword>
	<keyword>Head &amp; Neck</keyword>
</DOC>